Hemoglobin glutamer-250 (bovine) - HbO2 Therapeutics

Drug Profile

Hemoglobin glutamer-250 (bovine) - HbO2 Therapeutics

Alternative Names: Bovine haemoglobin - HbO2 Therapeutics; Bovine hemoglobin - OPK Biotech; HBOC-201; Hemoglobin glutamer-250 - HbO2 Therapeutics; Hemopure

Latest Information Update: 28 Feb 2017

Price : $50

At a glance

  • Originator Biopure Corporation
  • Developer Biopure Corporation; HbO2 Therapeutics
  • Class Haemoglobins
  • Mechanism of Action Haemoglobin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaemia
  • Phase II Ischaemia; Shock

Most Recent Events

  • 28 Feb 2017 No development reported - Phase-II for Anaemia in Greece (IV) (NCT00301535)
  • 26 Jun 2015 Phase-II clinical trials in Ischaemia in South Africa, Europe (IV)
  • 26 Jun 2015 Phase-II clinical trials in Shock in South Africa (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top